Treatment outcomes for HIV and MDR-TB co-infected adults and children: Systematic review and meta-analysis

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 8, 2015, Pages 969-978

  Isaakidis, P ^a,b   Casas, E C ^a   Das, M ^a   Tseretopoulou, X ^b   Ntzani, E E ^b   Ford, N ^c  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Human immunodeficiency virus AIDS; Meta analysis; Mortality; Multidrug resistant tuberculosis; Treatment success

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TUBERCULOSTATIC AGENT;

COHORT ANALYSIS; EARLY DIAGNOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS (TOPIC); METHODOLOGY; MIXED INFECTION; MONTE CARLO METHOD; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; AGE; CHILD; HIV INFECTIONS; INCIDENCE; META ANALYSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADULT; AGE FACTORS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CHILD; HIV INFECTIONS; HUMANS; INCIDENCE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84938275214     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.15.0123     Document Type: Review

References (52)

1. World Health Organization. Global tuberculosis report 2014. WHO/HTM/TB/2014.08. Geneva. Switzerland: WHO, 2014.
2. Falzon D, Jaramillo E, Wares F, Zignol M, Floyd K, Raviglione M C. Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infect Dis 2013; 13: 690-697.
3. Ettehad D, Schaaf H S, Seddon J A, Cooke G S, Ford N. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 449-456.
4. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015.WHOprogress report 2011. WHO/HTM/TB/2011.3. Geneva, Switzerland: WHO, 2011.
5. Mesfin Y M, Hailemariam D, Biadglign S, Kibret K T. Association between HIV/AIDS and multidrug resistance tuberculosis: a systematic review and meta-analysis. PLOS ONE 2014; 9: e82235.
6. Quy H T, Cobelens F G, Lan N T, Buu T N, Lambregts C S, Borgdorff M W. Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Viet Nam. Int J Tuberc Lung Dis 2006; 10: 45-51.
7. Wells C D, Cegielski J P, Nelson L J, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007; 196 (Suppl 1): S86-S107.
8. Gandhi N R, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-1843.
9. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: WHO, 2013.
10. Arentz M, Pavlinac P, Kimerling M E, et al. Use of antiretroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review. PLOS ONE 2012; 7: e47370.
11. Moher D, Liberati A, Tetzlaff J, Altman D G, Group P. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269.
12. Pearce E C, Woodward J F, Nyandiko W M, Vreeman R C, Ayaya S O. A systematic review of clinical diagnostic systems used in the diagnosis of tuberculosis in children. AIDS Res Treat 2012; 2012: 401896.
13. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
14. Toczek A, Cox H, du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2013; 17: 299-307.
15. Johnston J C, Shahidi N C, Sadatsafavi M, Fitzgerald J M. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLOS ONE 2009; 4: e6914.
16. Viswanathan M, Berkman N D, Dryden DM, Hartling L. Assessing risk of bias and confounding in observational studies of interventions or exposures: further development of the RTI item bank. Methods Research Report. AHRQ Publication No. 13 EHC106-EF. Rockville, MD, USA: Agency for Healthcare Research and Quality, 2013.
17. Freeman M F, Tukey J W. Transformations related to the angular and the square root. Ann Math Statist 1950; 21: 607-611.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
19. Higgins J P, Thompson S G, Deeks J J, Altman D G.Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
20. Flament-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of multi-drug-resistant tuberculosis in France: a nationwide casecontrol study. Am J Respir Crit Care Med 1999; 160: 587-593.
21. Gonzalez Montaner L J, Alberti F, Palmero D. Multidrugresistant tuberculosis associated with AIDS. Bull Acad Natl Med 1999; 183: 1085-1096.
22. Telzak E E, Chirgwin K D, Nelson E T, et al. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health. Int J Tuberc Lung Dis 1999; 3: 337-343.
23. Burgos M, Gonzalez L C, Paz E A, et al. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis 2005; 40: 968-975.
24. Ferrara G, Richeldi L, Bugiani M, et al. Management of multidrug-resistant tuberculosis in Italy. Int J Tuberc Lung Dis 2005; 9: 507-513.
25. Munsiff S S, Ahuja S D, Li J, Driver C R. Public-private collaboration for multidrug-resistant tuberculosis control in New York City. Int J Tuberc Lung Dis 2006; 10: 639-648.
26. Eker B, Ortmann J, Migliori G B, et al. Multidrug-and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 2008; 14: 1700-1706.
27. Shean K P, Willcox P A, Siwendu S, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis 2008; 12: 1182-1189.
28. Isaakidis P, Cox H S, Varghese B, et al. Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIVinfected patients in a slum setting in Mumbai, India. PLOS ONE 2011; 6: e28066.
29. Farley J E, Ram M, Pan W, et al. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLOS ONE 2011; 6: e20436.
30. Kvasnovsky C, Kurbatova E V, Odendaal R, Wolfgang M, Ershova J, Cegielski J P. HIV infection in patients with multidrug-resistant tuberculosis from the Preserving Effective TB Treatment Study. Am J Respir Crit Care Med 183; 2011: A1821.
31. Palacios E, Franke M, Mu noz M, et al. HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. Int J Tuberc Lung Dis 2012; 16: 348-354.
32. Brust J C, Berman A R, Zalta B, et al. Chest radiograph findings and time to culture conversion in patients with multidrugresistant tuberculosis and HIV in Tugela Ferry, South Africa. PLOS ONE 2013; 8: e73975.
33. Satti H, McLaughlinMM, Hedt-Gauthier B, et al. Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho. PLOS ONE 2012; 7: e46943.
34. Mdluli N. MDR-TB treatment outcomes among HIV and non-HIV infected patients in Swaziland: a review of routinely collected data. 44th World Conference on Lung Health, Paris, France, 30 October-3 November 2013. Int J Tuberc Lung Dis 2013: 17 (12 Suppl 2): S431 [Abstract PC-799-03].
35. Cox H, Hughes J, Daniels J, et al. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis 2014; 18: 441-448.
36. Khann S, Mao T E, Tan K, Rajendra Y. Using community-based care to achieve low defaulter rates among MDR-TB patients of Cambodia. 45thWorld Conference on Lung Health, Barcelona, Spain, 28 October-1 November 2014. Int J Tuberc Lung Dis 2014: 18 (Suppl 1): S499. [Abstract PD-1174-01].
37. Mikiashvili L Kikvidze, M. Impact of comorbidities on multidrug-resistant tuberculosis outcomes: a cohort study. 44th World Conference on Lung Health, Paris, France, 30 October-3 November 2013. Int J Tuberc Lung Dis 2013: 17 (12 Suppl 2): S372 [Abstract PC-724-02].
38. Kokebu D, Hurtado R, Ejara E, et al. Treatment outcomes from a collaborative multidrug-resistant tuberculosis treatment programme in Ethiopia. 44th World Conference on Lung Health, Paris, France, 30 October-3 November 2013. Int J Tuberc Lung Dis 2013: 17 (12 Suppl 2): S237 [Abstract OP-180-02].
39. Charles M, Vilbrun S C, Koenig S P, et al. Treatment outcomes for patients with multidrug-resistant tuberculosis in postearthquake Port-au-Prince, Haiti. Am J Trop Med Hyg 2014; 91; 715-772.
40. ZetolaNM, Modongo C, Moonan P K, et al. Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolateswith phenotypic heterogeneity in results of drug-susceptibility tests. J Infect Dis 2014; 209: 1754-1763.
41. Padayatchi N, Abdool Karim S S, Naidoo K, Grobler A, Friedland G. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. Int J Tuberc Lung Dis 2014; 18: 147-154.
42. Post F A, Grint D, Werlinlurd A M, et al. Multidrug-resistant tuberculosis in HIV positive patients in Eastern Europe. J Infect 2014; 68: 259-263.
43. Mekhdiyev R, Auer C, Gurbanova E, et al. Good treatment outcomes among prisoners with DRTB: hope from Baku, Azerbaijan and challenge to the TB world. 45th World Conference on Lung Health, Barcelona, Spain, 28 October-1 November 2014. Int J Tuberc Lung Dis 2014: 18 (Suppl 1): S346. [Abstract PD-952-31]
44. Seddon J A, Hesseling A C,Willemse M, Donald P R, Schaaf H S. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin Infect Dis 2012; 54: 157-166.
45. Satti H, McLaughlin M M, Omotayo D B, et al. Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence. PLOS ONE 2012; 7: e37114.
46. Seddon J A, Hesseling A C, Godfrey-Faussett P, Schaaf H S. High treatment success in children treated for multidrugresistant tuberculosis: an observational cohort study. Thorax 2014; 69: 458-464.
47. Hicks R M, Padayatchi N, Shah N S, et al. Malnutrition associated with unfavorable outcome and death among South African MDR-TB and HIV co-infected children. Int J Tuberc Lung Dis 2014; 18: 1074-1079.
48. Mugabo P, Adewumi A, Theron D, Burger A, Van Zyl L. Do HIV infection and antiretroviral therapy influence multidrugresistant tuberculosis treatment outcomes? Acta Clinica Belgica 2013; 68: 456.
49. Ahuja S D, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLOS MED 2012; 9: e1001300.
50. Clayden P, Collins S, Daniels C, et al. HIV, HCV, and TB. Pipeline Report. Drugs, diagnostics, vaccines, preventive technologies, research toward a cure, and immune-based and gene therapies in development. New York,NY, USA & London, UK: HIV i-Base/Treatment Action Group, 2014.
51. GlerMT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
52. Diacon A H, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.